Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVXVNASDAQ:DYAINASDAQ:ERYPNASDAQ:LOGCNASDAQ:SURF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsDYAIDyadic International$0.93-1.0%$1.03$0.91▼$2.20$28.28M0.8854,873 shs112,279 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/ALOGCLogicBio Therapeutics$7.30+0.7%$2.06$0.26▼$3.77$191.84M2.06168,718 shs73,796 shsSURFSurface Oncology$1.07$1.01$0.56▼$1.43$65.08M1.75430,375 shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DYAIDyadic International0.00%-6.80%-4.71%-25.52%-36.67%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%LOGCLogicBio Therapeutics0.00%+9.77%+9.28%+5.95%+26.96%SURFSurface Oncology0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ADYAIDyadic International1.9943 of 5 stars3.54.00.00.00.01.70.0ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/ALOGCLogicBio Therapeutics1.4315 of 5 stars0.04.00.04.70.60.80.6SURFSurface OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVXVBiondVax Pharmaceuticals 0.00N/AN/AN/ADYAIDyadic International 3.00Buy$6.00544.47% UpsideERYPERYTECH Pharma 0.00N/AN/AN/ALOGCLogicBio Therapeutics 0.00N/AN/AN/ASURFSurface Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ADYAIDyadic International$3.49M8.03N/AN/A$0.08 per share11.64ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88LOGCLogicBio Therapeutics$287M0.67N/AN/A$8.96 per share0.81SURFSurface Oncology$30M2.17N/AN/A$0.81 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ADYAIDyadic International-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/ALOGCLogicBio Therapeutics-$317M-$5.79N/A∞N/A-141.03%-81.98%-52.13%N/ASURFSurface Oncology-$63.59M-$1.53N/AN/AN/AN/A-107.81%-65.57%N/ALatest SURF, DYAI, BVXV, LOGC, and ERYP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/9/2025Q1 2025LOGCLogicBio TherapeuticsN/A-$0.27N/A-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ASURFSurface OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVXVBiondVax PharmaceuticalsN/A4.124.12DYAIDyadic International5.403.983.98ERYPERYTECH Pharma0.323.653.65LOGCLogicBio TherapeuticsN/A31.6031.60SURFSurface OncologyN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVXVBiondVax Pharmaceuticals11.83%DYAIDyadic International27.95%ERYPERYTECH Pharma1.09%LOGCLogicBio Therapeutics46.05%SURFSurface Oncology37.21%Insider OwnershipCompanyInsider OwnershipBVXVBiondVax Pharmaceuticals6.03%DYAIDyadic International29.50%ERYPERYTECH Pharma1.94%LOGCLogicBio Therapeutics8.10%SURFSurface Oncology12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableDYAIDyadic International730.09 million21.21 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableLOGCLogicBio Therapeutics6226.28 million24.16 millionOptionableSURFSurface Oncology3560.82 million53.53 millionNot OptionableSURF, DYAI, BVXV, LOGC, and ERYP HeadlinesRecent News About These CompaniesHepatocellular Carcinoma Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 7, 2025 | theglobeandmail.comNovel Leukemia Target Found in RNA-Binding Cell Surface ProteinApril 23, 2025 | genengnews.comGInternational conference at the Thangam Cancer Center - Experts delivering edging Tech in Medical field at NamakkalJanuary 25, 2025 | msn.comThree-days conference at Thangam Cancer Center; providing insights on the international norms to treat advanced cancersJanuary 8, 2025 | news.webindia123.comNResearch Spotlight: Improving liver cancer outcomes through enhanced immunotherapyDecember 14, 2024 | eurekalert.orgECan estrogen cream combat skin aging signs? Here’s what dermatologists say.November 14, 2024 | washingtonpost.com‘Tremendous potential’: Cell therapy shows promise in treating deadly brain cancer in new trialNovember 14, 2024 | msn.comCAR-T therapy offers hope against an incurable brain tumor: patient shows no sign of disease after four yearsNovember 14, 2024 | msn.comTreatment offers promise for 'terrible, terrible' brain cancer in young peopleNovember 14, 2024 | msn.comQ3 2024 Heron Therapeutics Inc Earnings CallNovember 13, 2024 | finance.yahoo.comHow wearable tech can help women fight breast cancerNovember 13, 2024 | livemint.comAura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12, 2024 | markets.businessinsider.comVANCE trial marks milestone in t cell therapy for solid tumorsNovember 12, 2024 | msn.comLargest T cell clinical trial in solid tumors explores potential for precision immunotherapyNovember 12, 2024 | medicalxpress.comMNammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myelomaNovember 11, 2024 | pharmabiz.comPLargest T cell clinical trial in solid tumors heralds new era in precision immunotherapyNovember 11, 2024 | eurekalert.orgECAR T-Cell Therapy for Kidney Cancer Builds on Efficacy RecordNovember 9, 2024 | medpagetoday.comMNeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comEpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific MeetingsNovember 5, 2024 | finance.yahoo.comAntibody-based treatment for the most aggressive type of breast cancer could also treat other cancersNovember 4, 2024 | medicalxpress.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSURF, DYAI, BVXV, LOGC, and ERYP Company DescriptionsBiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Dyadic International NASDAQ:DYAI$0.93 -0.01 (-0.96%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.95 +0.02 (+1.83%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.LogicBio Therapeutics NASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Surface Oncology NASDAQ:SURFSurface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
